Ayretrade Inc (SUMM) 0.0610 $SUMM Summit Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board

Oct 11, 2015 at 1:35 AM

Ayretrade Inc (SUMM) 0.0610 $SUMM

Summit Therapeutics Presents Additional Data From Phase 1b Modified Diet Clinical Trial of SMT C1100 in DMD Patients at WMS
GlobeNewswire - Wed Sep 30, 6:00AM CDT
-- 10 of 12 Patients Achieved Plasma Concentrations Expected to Increase Utrophin Levels by Approximately 30% or Greater
SMMT: 10.35 (+0.12)

Summit Therapeutics to Present Phase 1b Clinical and Preclinical DMD Data at the 20th International Congress of the World Muscle Society
GlobeNewswire - Thu Sep 24, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection, today announced that it will present additional clinical data from its Phase 1b modified diet trial of SMT C1100 for the treatment of DMD, as well as preclinical data supporting SMT C1100 and the broader utrophin modulation pipeline, at the 20 International Congress of the World Muscle Society, taking place 30 September-4 October 2015 in Brighton, UK.
SMMT: 10.35 (+0.12)

Summit Therapeutics Presents New Positive Preclinical Data on Novel C. difficile Antibiotic SMT19969 at ICAAC 2015
GlobeNewswire - Fri Sep 18, 7:30AM CDT
Summit (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection ('CDI'

, announces new preclinical data on SMT19969, a novel and selective oral antibiotic for the treatment of CDI, will be presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy ('ICAAC 2015'

being held in San Diego, USA from September 17-21, 2015.
SMMT: 10.35 (+0.12)

Summit Therapeutics Completes Targeted Enrolment for SMT19969 Phase 2 Trial for C. difficile Infection
GlobeNewswire - Thu Sep 10, 6:00AM CDT
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and Clostridium difficile infection ('CDI'

, today announced the completion of patient enrolment into the CoDIFy Phase 2 proof of concept trial of SMT19969 for the treatment of CDI. Patient dosing and follow-up is continuing and top-line results are expected in the fourth quarter of 2015. SMT19969 is a novel, oral antibiotic designed to selectively target C. difficile bacteria while not harming the gut microbiome that is essential in protecting against disease recurrence.
SMMT: 10.35 (+0.12)

Summit Therapeutics to Report Second Quarter 2015 Financial Results on 27 August 2015
GlobeNewswire - Mon Aug 24, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its second quarter financial results for the period ending 31 July 2015 on Thursday, 27 August 2015.
SMMT: 10.35 (+0.12)

Summit Therapeutics Announces Phase 1b Modified Diet Clinical Trial Achieves Primary Objective in Duchenne Muscular Dystrophy
GlobeNewswire - Mon Aug 17, 6:00AM CDT
-- Primary Objective Met; Plasma Absorption of SMT C1100 Observed at a Level Suitable for Further Development
SMMT: 10.35 (+0.12)

Summit Financial Group Reports Second Quarter and First Half 2015 Results
GlobeNewswire - Mon Jul 27, 5:00AM CDT
Summit Financial Group, Inc. ("Company" or "Summit"

(NASDAQ:SMMF) today reported second quarter 2015 net income applicable to common shares of $4.01 million, or $0.38 per diluted share, compared to $2.24 million, or $0.25 per diluted share, for the second quarter of 2014, representing an increase of 79.1 percent, or 52.0 percent per diluted share. Q2 2015 earnings compared to Q2 2014 were positively impacted by an $802,000 decline in write-downs of foreclosed properties, a $500,000 decrease in provision for loan losses, and a $1.14 million increase in net interest income.
SMMF: 11.64 (+0.04)

Steven W. Lieberman Is Recognized, For A Record 13th Consecutive Year, As Summit Financial Resources Inc.'s Investment Leader
PR Newswire - Wed Jul 15, 8:30AM CDT
One of the largest independent financial planning and wealth management firms in the greater New York City area, Summit Financial Resources, Inc., announced that Steven W. Lieberman, MBA, CFP® was named the firm's 2014 Investment Leader. For over a dozen consecutive years, he has consistently held this recognition as Summit's top-ranking investment management practice.

Summit Therapeutics plc Annual General Meeting Statement
GlobeNewswire - Tue Jul 14, 6:14AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and C. difficile infection ('CDI'

, is today holding its Annual General Meeting at 1:30pm BST / 8:30am EDT at the offices of Fasken Martineau, 17 Hanover Square, London, W1S 1HU. During the meeting, the Company's Chief Executive Officer, Glyn Edwards, will make a statement, a copy of which is below.
SMMT: 10.35 (+0.12)

Summit Therapeutics Publishes Preclinical Data on Disease-Modifying Potential of Utrophin Modulation in DMD
GlobeNewswire - Mon Jul 13, 6:00AM CDT
-- Publication in Human Molecular Genetics supports utrophin modulation as mechanism to treat DMD regardless of mutation status
SMMT: 10.35 (+0.12)

Summit Therapeutics Receives FDA Fast Track Designation for Novel Antibiotic SMT19969 in the Treatment of C. difficile Infection
GlobeNewswire - Wed Jul 08, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection ('CDI'

, announces that the US Food and Drug Administration ('FDA'

has granted Fast Track designation for the Company's novel antibiotic for the treatment of CDI. SMT19969 is a highly selective antibiotic candidate currently being evaluated in a Phase 2 proof of concept trial in CDI patients in North America.
SMMT: 10.35 (+0.12)

Summit Therapeutics Granted Key Patent by European Patent Office for Utrophin Modulator SMT C1100 in the Treatment of DMD
GlobeNewswire - Tue Jul 07, 6:00AM CDT
-- Patent emerges from opposition period with no opposition filed with EPO
SMMT: 10.35 (+0.12)

Summit Therapeutics to Present New Preclinical Data on Utrophin Modulator Programme at PPMD Connect Conference
GlobeNewswire - Fri Jun 19, 5:59AM CDT
-- Treatment with SMT C1100 and SMT022357 results in increased utrophin along the length of muscle fibers leading to disease reduction in DMD models
SMMT: 10.35 (+0.12)

Summit to Present at JMP Securities Life Sciences Conference
GlobeNewswire - Mon Jun 15, 6:04AM CDT
Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that Mr Erik Ostrowski, Summit's Chief Financial Officer, is scheduled to present at JMP Securities Life Sciences Conference at 12:00 noon EDT (5:00 pm BST) on Tuesday, 23 June 2015 in New York City.
SMMT: 10.35 (+0.12)

Summit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015
GlobeNewswire - Thu Jun 11, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and C. difficile infection ('CDI'

, today reports its financial results for the three months ended 30 April 2015.
SMMT: 10.35 (+0.12)

Summit Therapeutics to Report First Quarter 2015 Financial Results on 11 June 2015
GlobeNewswire - Fri Jun 05, 6:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the period ending 30 April 2015 on Thursday, 11 June 2015.
SMMT: 10.35 (+0.12)

Triad Advisors Welcomes Summit Financial Consultants To Its Broker-Dealer And Hybrid RIA Platform
PR Newswire - Thu May 21, 8:15AM CDT
Triad Advisors, Inc. today announced that Summit Financial Consultants ("Summit"

has transitioned to the Triad Advisors broker-dealer and hybrid RIA multi-custodial platform. Summit oversees client assets of approximately $225 million, as of March 31, 2015, offering comprehensive independent financial advisory services to affluent and high-net-worth clients. Triad Advisors is a leading independent broker-dealer supporting independent hybrid financial advisory practices and registered investment advisory (RIA) firms, and is a wholly owned subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT: LTS).
LTS: 2.38 (+0.01)

Shane O'Grady Joins TAB Bank's Business Development Team
Marketwired - Thu May 14, 10:30AM CDT
TAB Bank is pleased to announce the addition of Shane O'Grady (480-209-5400, shane.ogrady@tabbank.com) to their business development team as Vice President and Business Development Officer. Shane will be based in Phoenix, AZ and will be responsible for sourcing new business opportunities by providing asset-based and factoring working capital facilities to commercial entities with annual revenues of $2 million to $150 million.

Summit Therapeutics Reports Financial Results for the Fiscal Year Ended 31 January 2015
GlobeNewswire - Wed May 06, 6:34AM CDT
Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD'

and C. difficile infection ('CDI'

, today reports its financial results for the year ended 31 January 2015.
SMMT: 10.35 (+0.12)

Summit Therapeutics Provides Notice of Full Year Financial Results
GlobeNewswire - Fri May 01, 1:00AM CDT
Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its full year financial results for the year ended 31 January 2015 on Wednesday 6 May 2015.
SMMT: 10.35 (+0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...